

Substitute for form 1449/PTO (Revised 07/2007) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/556,711
				Filing Date	November 13, 2006
				First Named Inventor	Kanazawa et al.
				Art Unit	1635
				Examiner Name	Gibbs, Terra C.
Sheet	1	of	1	Attorney Docket Number	051009/303044

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	EP 0 614 977 B1	09-14-1994	The General Hospital Corporation		
	2	WO 00/52210	09-08-2000	Variagenics, Inc.		

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	3	GOTO, J. <i>et al.</i> , "Suppression of Huntingtin Gene Expression by SiRNA: A Possible Therapeutic Tool for Huntington's Disease," <i>Neurology</i> , 2003, p. A286, Vol. 60, No. 5, Suppl. 1.	Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.